MX2013000547A - Composicion farmaceutica combinada y metodos para el tratamiento de los transtornos del sistema genitourinario. - Google Patents
Composicion farmaceutica combinada y metodos para el tratamiento de los transtornos del sistema genitourinario.Info
- Publication number
- MX2013000547A MX2013000547A MX2013000547A MX2013000547A MX2013000547A MX 2013000547 A MX2013000547 A MX 2013000547A MX 2013000547 A MX2013000547 A MX 2013000547A MX 2013000547 A MX2013000547 A MX 2013000547A MX 2013000547 A MX2013000547 A MX 2013000547A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- methods
- antibody
- activated
- system disorders
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 210000002229 urogenital system Anatomy 0.000 title 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 abstract 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 2
- 230000003511 endothelial effect Effects 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención proporciona una composición farmacéutica que comprende a) una forma activada potenciada de un anticuerpo contra el antígeno prostático específico, y b) una forma activada potenciada de un anticuerpo contra la NO sintasa endotelial. Se proporcionan varias modalidades y variantes. La invención proporciona métodos de tratamiento de la hiperplasia prostática benigna y las disfunciones eréctiles y diversos métodos de administración que comprenden administrar una composición farmacéutica que comprende a) una forma activada potenciada de un anticuerpo contra el antígeno prostático específico, y b) una forma activada potenciada de un anticuerpo contra la NO sintasa endotelial.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129295/15A RU2531049C2 (ru) | 2010-07-15 | 2010-07-15 | Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы |
| RU2010129294/15A RU2542414C2 (ru) | 2010-07-15 | 2010-07-15 | Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций |
| RU2011127053/15A RU2565400C2 (ru) | 2011-07-01 | 2011-07-01 | Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы |
| PCT/IB2011/002417 WO2012007849A2 (en) | 2010-07-15 | 2011-07-15 | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013000547A true MX2013000547A (es) | 2014-04-14 |
| MX354187B MX354187B (es) | 2018-02-16 |
Family
ID=44899158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000547A MX354187B (es) | 2010-07-15 | 2011-07-15 | Composicion farmaceutica combinada y metodos para el tratamiento de los trastornos del sistema genitourinario. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20130064860A1 (es) |
| EP (1) | EP2593483A2 (es) |
| JP (3) | JP2013538791A (es) |
| CN (1) | CN103282384A (es) |
| AU (1) | AU2011278042B2 (es) |
| CA (1) | CA2805094A1 (es) |
| DE (1) | DE112011102350T5 (es) |
| EA (1) | EA029860B1 (es) |
| ES (1) | ES2425314R1 (es) |
| FR (1) | FR2962655A1 (es) |
| GB (1) | GB2495885B (es) |
| IT (1) | ITTO20110631A1 (es) |
| MX (1) | MX354187B (es) |
| MY (1) | MY165267A (es) |
| NZ (1) | NZ606775A (es) |
| SG (2) | SG10201505564VA (es) |
| WO (1) | WO2012007849A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| NZ606767A (en) * | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| AU2011287288A1 (en) | 2010-07-15 | 2013-03-07 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
| DE112011102412T5 (de) | 2010-07-21 | 2013-07-04 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden |
| MX2013000807A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion. |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| KR102166544B1 (ko) * | 2013-10-23 | 2020-10-16 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2197266C1 (ru) * | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
| RU2001134982A (ru) * | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| WO2008007868A1 (en) * | 2006-07-13 | 2008-01-17 | Mazence Inc. | Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
| TWI345470B (en) | 2003-03-14 | 2011-07-21 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
| NZ554278A (en) * | 2004-09-03 | 2009-11-27 | Chr Hansen As | Fermented milk or vegetable proteins comprising receoptor ligand and uses thereof |
| CA2647932C (en) * | 2006-04-04 | 2011-06-07 | Dong A Pharm. Co. Ltd. | Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound |
| RU2438707C2 (ru) * | 2006-06-06 | 2012-01-10 | Олег Ильич Эпштейн | Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе |
| EP2395021A1 (en) * | 2006-06-06 | 2011-12-14 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| NZ606767A (en) * | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| CA2805091A1 (en) * | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor |
| BR112013000842A2 (pt) * | 2010-07-15 | 2016-06-07 | Oleg Lliich Epshtein | composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa. |
-
2011
- 2011-07-15 GB GB1302651.3A patent/GB2495885B/en not_active Expired - Fee Related
- 2011-07-15 IT IT000631A patent/ITTO20110631A1/it unknown
- 2011-07-15 WO PCT/IB2011/002417 patent/WO2012007849A2/en active Application Filing
- 2011-07-15 NZ NZ606775A patent/NZ606775A/en not_active IP Right Cessation
- 2011-07-15 US US13/135,898 patent/US20130064860A1/en not_active Abandoned
- 2011-07-15 FR FR1156476A patent/FR2962655A1/fr not_active Withdrawn
- 2011-07-15 JP JP2013519179A patent/JP2013538791A/ja active Pending
- 2011-07-15 SG SG10201505564VA patent/SG10201505564VA/en unknown
- 2011-07-15 CN CN201180044500XA patent/CN103282384A/zh active Pending
- 2011-07-15 ES ES201390004A patent/ES2425314R1/es active Pending
- 2011-07-15 MY MYPI2013000108A patent/MY165267A/en unknown
- 2011-07-15 MX MX2013000547A patent/MX354187B/es active IP Right Grant
- 2011-07-15 SG SG2013002308A patent/SG187036A1/en unknown
- 2011-07-15 DE DE112011102350T patent/DE112011102350T5/de not_active Withdrawn
- 2011-07-15 EP EP11784771.5A patent/EP2593483A2/en not_active Ceased
- 2011-07-15 CA CA2805094A patent/CA2805094A1/en not_active Abandoned
- 2011-07-15 EA EA201300129A patent/EA029860B1/ru not_active IP Right Cessation
- 2011-07-15 AU AU2011278042A patent/AU2011278042B2/en not_active Ceased
-
2016
- 2016-07-01 JP JP2016131664A patent/JP2016199570A/ja active Pending
-
2018
- 2018-04-26 JP JP2018085388A patent/JP2018150322A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2425314R1 (es) | 2014-07-09 |
| WO2012007849A3 (en) | 2012-04-05 |
| ITTO20110631A1 (it) | 2012-01-16 |
| GB201302651D0 (en) | 2013-04-03 |
| NZ606775A (en) | 2015-08-28 |
| ES2425314A2 (es) | 2013-10-14 |
| WO2012007849A2 (en) | 2012-01-19 |
| EA201300129A1 (ru) | 2013-12-30 |
| SG10201505564VA (en) | 2015-09-29 |
| EA029860B1 (ru) | 2018-05-31 |
| DE112011102350T5 (de) | 2013-04-18 |
| AU2011278042A1 (en) | 2013-03-07 |
| JP2016199570A (ja) | 2016-12-01 |
| JP2013538791A (ja) | 2013-10-17 |
| MY165267A (en) | 2018-03-15 |
| FR2962655A1 (fr) | 2012-01-20 |
| GB2495885B (en) | 2017-11-22 |
| MX354187B (es) | 2018-02-16 |
| AU2011278042B2 (en) | 2017-02-16 |
| SG187036A1 (en) | 2013-02-28 |
| US20130064860A1 (en) | 2013-03-14 |
| JP2018150322A (ja) | 2018-09-27 |
| CN103282384A (zh) | 2013-09-04 |
| GB2495885A (en) | 2013-04-24 |
| EP2593483A2 (en) | 2013-05-22 |
| CA2805094A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2495885A (en) | Combination pharmaceutical composition and methods of treating genitourinary system disorders | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
| EA201590165A1 (ru) | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения | |
| EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
| MX360254B (es) | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. | |
| MX2013010286A (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
| DK2331118T3 (da) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers | |
| EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
| EA201100268A1 (ru) | Вакцина | |
| EA201690782A1 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
| WO2010093705A3 (en) | Synthetic rna-based agonists of tlr7 | |
| EA201290322A1 (ru) | Лечение желудочно-кишечных расстройств | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| IN2012DN02471A (es) | ||
| EA201071248A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| ATE528013T1 (de) | Impfstoff-zusammensetzungen | |
| NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
| MX349948B (es) | Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |